TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01366313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: initial doses was 1.5g, with dose adjustment intervals of 0.5g . with maximum dose 2.5 g as an only starting dose / 24 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Initial of morphine was 5mg, with dose adjustment intervals 1 mg .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol- Morphine
Description: The initial doses of paracetamol and morphine were 1.5g and 3mg, respectively in the paracetamol-morphine combination group with dose adjustment intervals of 0.25g for paracetamol and 0.5mg for morphine.
Study: NCT04998890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adventure-based cognitive behavioral intervention
Description: The adventure-based cognitive behavioral intervention is a combination of cognitive behavioral therapy and adventure training. The intervention program is delivered in a 39-hour general education course entailed Improving Mental Health for University Success in a public university in Hong Kong. The program includes 6 lectures, 5 workshops, 5 adventure games and an adventure day camp. Students are divided into two groups in workshop to practise CBT skills to deal with their own issues.
Study: NCT03675360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet
Description: Behavioral modification to reduce carbohydrate consumption. Target \<40 g net carbohydrates per day for first 3 months; \<60 g net carbohydrates per day for months 4 onwards. The intervention will consist of 4 weekly individual counseling sessions, followed by 4 group sessions held every other week, with phone follow-ups in between group sessions. For the last 3 months of the study, there will be 3 monthly group sessions and 3 telephone follow-ups.~At baseline, participants will receive written information with standard physical activity recommendations.
Study: NCT03746925

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Anterior Approach (DAA)
Description: Direct Anterior Approach surgery to replace the hip.
Study: NCT04297605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pemetrexed (Chemotherapy)
Description: 500 mg/m2 day 1 of 21 day cycle (for non-squamous only)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (Chemotherapy)
Description: 100 mg/m2 days 1,8 of 21 day cycle x 4 cycles
Study: NCT01225380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9190
Description: GS-9190 capsule, 20 mg BID, 16 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9256
Description: GS-9256 capsule, 150 mg BID, 16 or 24 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegasys®
Description: peginterferon alfa-2a, (solution for injection) 180 µg/week, up to 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus®
Description: ribavirin 200 mg tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day \>/= 75 kg) divided twice daily (BID), up to 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9190 placebo
Description: placebo matching GS-9190 capsule BID, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9256
Description: GS-9256 capsule, 150 mg BID, 24 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegasys®
Description: peginterferon alfa-2a (solution for injection) 180 µg/week, up to 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus®
Description: ribavirin 200 mg tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day \>/= 75 kg) divided twice daily (BID), up to 48 weeks
Study: NCT03746925

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SuperPATH
Description: SuperPATH approach surgery to replace the hip.
Study: NCT05203601

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIBP-03
Description: Stage 1:~Six dose groups of 2, 5, 10, 15, 20 and 40 mg/kg were planned. Dose increments began at 2 mg/kg using accelerated titration. In the first dose group, after the first patient was injected with Sibp-03, if the subject developed toxicity grade ≥2（CTCAE v5.0 standard）within 21 days of initial administration，then the subject increased to 3 and the study design method in this dose level convert to 3+3. If the subject didn't develop toxicity grade ≥2, then the study of the second and next dose group can be carried out using 3+3 incremental design.~Stage 2:~Cohort 1 included patients with advanced head and neck squamous cell carcinoma and cohort 2 included patients with breast cancer. According to the results of dose escalation stage and similar drug trials, 5mg/kg and 10mg/kg dose levels were selected to enter this phase. Each cohort will be extended to include 6-8 subjects to receive this product in combination with the standard treatment study.
Study: NCT03961763

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA+DHA
Description: 4 g/day EPA+DHA in tablets of 1g, 4 tablets daily, over 8 weeks (56 days)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 g/day olive oil placebo in tablets of 1g, 4 tablets daily, over 8 weeks (56 days).
Study: NCT04687410

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProControl, MediGlobe
Description: standard 22G FNA needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TopGain, Medi-Globe
Description: novel 22G crown-cut FNB needle
Study: NCT04187443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-553
Description: MS-553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-553
Description: MS-553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-553
Description: MS-553
Study: NCT03860298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviFUS System
Description: Using NaviFUS System treatment for 10 minutes in drug resistant epilepsy. The site of the NaviFUS exposure is where the future surgery will be removed. Patients will concomitant use of anti-epileptic drugs (AEDs).
Study: NCT00889655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golytely (polyethylene glycol)
Description: 4 L of golytely, in split dosing. If the patient has a morning colonoscopy, they will take 2 L of golytely over 2 hours the morning prior to their procedure and repeat this at 6 pm the night prior to their procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MiraLax (polyethylene glycol 3350)
Description: 238 gm of MiraLax mixed in 64 oz of Gatorade, to be consumed in split dosing the day prior to scheduled colonoscopy.
Study: NCT01406119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-806
Description: ABT-806 will be administered by intravenous infusion.
Study: NCT02689804

Intervention type: DRUG
Group type: OTHER
Intervention: LNG-EC
Description: FDA-approved emergency contraceptive pill containing levonorgestrel 1.5mg

Intervention type: DRUG
Group type: OTHER
Intervention: LNG-EC
Description: FDA-approved emergency contraceptive pill containing levonorgestrel 1.5mg

Intervention type: DRUG
Group type: OTHER
Intervention: UPA-EC
Description: FDA-approved emergency contraceptive pill containing ulipristal acetate 30mg

Intervention type: DRUG
Group type: OTHER
Intervention: UPA-EC
Description: FDA-approved emergency contraceptive pill containing ulipristal acetate 30mg
Study: NCT01954238

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GCC-4401C
Description: * Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease.~* The dose selection for this clinical study was based on the safety, Pharmacokinetics and Pharmacodynamics results of the single dose study.~* GCC-4401C was well tolerated in the single ascending dose study up to the highest single oral dose administered of 80 mg from 2.5 mg in 48 subjects.~* The study consists of five cohorts (10 mg, 20 mg, 40 mg, 60 mg, and 80 mg) with eight subjects per cohort.~* In the 20 mg cohort, six additional subjects will receive rivaroxaban (Xarelto®) 20 mg as an active comparator in open-label fashion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GCC-4401C
Description: * Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease.~* The dose selection for this clinical study was based on the safety, Pharmacokinetics and Pharmacodynamics results of the single dose study.~* GCC-4401C was well tolerated in the single ascending dose study up to the highest single oral dose administered of 80 mg from 2.5 mg in 48 subjects.~* The study consists of five cohorts (10 mg, 20 mg, 40 mg, 60 mg, and 80 mg) with eight subjects per cohort.~* In the 20 mg cohort, six additional subjects will receive rivaroxaban (Xarelto®) 20 mg as an active comparator in open-label fashion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban (Xarelto®) 20 mg tablets for oral administration IMP, placebo and comparator will be administered the same time points. The comparator will be administered open-label 30 minutes after a standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GCC-4401C matching placebo(Capsule): Strength is not applicable. GCC-4401C and placebo will be administered double-blind after a 10 hours fast.
Study: NCT02992028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Nutrition (Vitamins) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Saline injection
Study: NCT02565316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepeta menthoides Boiss & Bohse freeze dried extract

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Study: NCT03425318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CNAP
Description: Application of CNAP in patients with ARDS
Study: NCT01225380

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GS-9190 placebo
Description: placebo matching GS-9190 capsule BID, 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GS-9256 placebo
Description: placebo matching GS-9256 capsule BID, 24 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pegasys®
Description: peginterferon alfa-2a (solution for injection) 180 µg/week, 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Copegus®
Description: ribavirin 200 mg tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day \>/= 75 kg) divided twice daily (BID), 48 weeks
Study: NCT03931746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Porcine xenograft
Description: The EZ-DERM™ porcine xenograft is a biosynthetic dressing made from porcine collagen containing aldehyde crosslinking. It has been most commonly applied to the management of 2nd degree burns, both partial-thickness and full-thickness defects. This dressing can be used for two healing purposes, either for primary healing or as an intermediate in the preparation for a skin graft
Study: NCT03557645

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Baseline Mechanical Ventilation
Description: The subjects will be kept in Volume Control Continuous Mandatory Ventilation (VC-CMV).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VHI With Inspiratory Pause
Description: Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory pause.
Study: NCT02078193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Patients will be converted from their MMF to Belatacept
Study: NCT00299819

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-545
Description: 0.3 mg/kg IV (n=6) at Study Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI 545
Description: 0.3 mg/kg IV (n=6) at Study Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-545
Description: 0.3 mg/kg IV (n=6) at Study Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-545
Description: 0.3 mg/kg IV (n=6) at Study Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-545
Description: 0.3 mg/kg IV (n=6) at Study Day 0
Study: NCT02346877

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Personalized Patient Counselling
Description: In the interventional cohort participants enrolled on the study will receive personalized patient counselling using the IMS-model based on the baseline BMQ results through a patient assistance program for patients on Enbrel (Etanercept) therapy.
Study: NCT04256980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib will be self-administered at 9mg Or 13.5mg as a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule
Study: NCT01688323

Intervention type: OTHER
Intervention: Collect Blood and Survey Instruments
Description: Each subject will be administered the appropriate surveys and blood draws over the course of the study.
Study: NCT01945944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (3%)
Description: 3mL of HTS given via nebulizer every 6hrs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% saline)
Description: 3mL of normal saline given via nebulizer every 6hrs
Study: NCT03557645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VHI Without Inspiratory Pause
Description: Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) without an inspiratory pause.
Study: NCT01442922

Intervention type: OTHER
Intervention: completion of the (VAS) for level of back pain
Description: Patients will complete the (VAS) pre-operatively and post-operatively at 6 wks, and 3, 6, 12, and 24 mos.

Intervention type: OTHER
Intervention: completion of the (OLBPQ) for assessment of function
Description: Patients will complete the (OLBPQ) pre-operatively and post-operatively at 6 wks, and 3, 6, 12, and 24 mos.
Study: NCT02949947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose
Description: 15 mg/kg by vein (up to 750 mg) over 15 min infusion. Dose repeated 1 week later.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplements
Description: Participants take iron supplements by mouth every day for up to 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24.
Study: NCT03708445

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cytology staining
Description: Two staining will be performed in cytology specimens obtained from same patient. The cytology specimen will be obtained through brushing cytology using endoscopic retrograde cholangiopancreatography~1. conventional cytology staining method~2. new cytology staining method using antibody of aminoacyl-tRNA synthetases
Study: NCT03576638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Accordion Pill Carbidopa/Levodopa
Description: AP 50/500 TID days 2-7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinemet CR 25Mg-100Mg Extended-Release Tablet
Description: 25/100 1.5 pills five times/day
Study: NCT01431339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Dalbavancin
Description: IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin/Linezolid
Description: IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg every 12 hours). Total duration of therapy is 10-14 days
Study: NCT03462784

Intervention type: OTHER
Intervention: Demographic, physical examination, data will becollected .
Description: Demographic data collected includ clinical diagnosis, sex, race, genotype, and phenotype.~Historical data included information regarding immunizations, infection exposures, surgical procedures, organ dysfunction(Organ dysfunction was defined as a history of requiring medical treatment for heart disease, diabetes (Type 1 or 2), hypoparathyroidism, hypothyroidism, growth hormone deficiency, or gonadal failure) age at transfusion initiation, chelation therapy, type of RBC product, transfusion reactions, and antigen matching. Data will be collected from chart review, patient interviews, blood banking records, and laboratory
Study: NCT04405323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06466
Description: hard capsules, orally, single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06466
Description: hard capsules, orally, single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200 and 300 mg, capsules, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200 and 300 mg, capsules, orally
Study: NCT00800111

Intervention type: PROCEDURE
Group type: OTHER
Intervention: endothelial keratoplasty
Description: Endothelial keratoplasty is surgical replacement of the corneal endothelial cell layer (the cell layer lining the inner surface of the cornea).
Study: NCT03782714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: It is a diode laser device that has laser set at low level, used for pain relief and inflammation reduction to induce healing
Study: NCT03848039

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil-9
Description: administration by intramuscular injection of the 9-valent HPV vaccine according to a 3-dose vaccination schedule (0, 2, 6 months).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administration by intramuscular injection of the placebo according to vaccination schedule of the 9-valent HPV vaccine (0, 2, 6 months)
Study: NCT02560753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T3D-959
Description: The 3mg dosage is supplied as 1mg capsules (three capsules, taken once daily by mouth) The 10mg dosage is supplied as 5mg capsules (two capsules, taken once daily by mouth) The 30mg dosage is supplied as either 5mg or 15mg capsules (six 5mg capsules or two 15mg capsules taken once daily by mouth) The 90mg dosage is supplied as 15mg capsules (six capsules, taken once daily by mouth)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T3D-959
Description: The 3mg dosage is supplied as 1mg capsules (three capsules, taken once daily by mouth) The 10mg dosage is supplied as 5mg capsules (two capsules, taken once daily by mouth) The 30mg dosage is supplied as either 5mg or 15mg capsules (six 5mg capsules or two 15mg capsules taken once daily by mouth) The 90mg dosage is supplied as 15mg capsules (six capsules, taken once daily by mouth)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T3D-959
Description: The 3mg dosage is supplied as 1mg capsules (three capsules, taken once daily by mouth) The 10mg dosage is supplied as 5mg capsules (two capsules, taken once daily by mouth) The 30mg dosage is supplied as either 5mg or 15mg capsules (six 5mg capsules or two 15mg capsules taken once daily by mouth) The 90mg dosage is supplied as 15mg capsules (six capsules, taken once daily by mouth)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T3D-959
Description: The 3mg dosage is supplied as 1mg capsules (three capsules, taken once daily by mouth) The 10mg dosage is supplied as 5mg capsules (two capsules, taken once daily by mouth) The 30mg dosage is supplied as either 5mg or 15mg capsules (six 5mg capsules or two 15mg capsules taken once daily by mouth) The 90mg dosage is supplied as 15mg capsules (six capsules, taken once daily by mouth)
Study: NCT03063944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAT Inhibitor OPB-111077
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03987971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture on GB26, every other day, 3 times a week, 2 weeks in total.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: Acupuncture on GB26, every other day, 3 times a week, 2 weeks in total.
Study: NCT01227291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL040012
Description: SYL040012 ophthalmic drops, daily single dose administration
Study: NCT04012619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Patients receive pemetrexed with cisplatin/carboplatin once every 3 weeks, and anlotinib (dose escalation) once daily on days 1-14.
Study: NCT03689634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Move For Surgery Preconditioning Program using a Wearable Activity Tracker (Fitbit) Intervention Group
Description: Participants randomized to this group will be be provided with a wearable activity tracker (Fitbit) for the duration of the study and asked to reach daily step goals.
Study: NCT02896075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30 Minute Comedy Video
Description: The intervention is a 30 minute video of a comedy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30 Minute Documentary Video
Description: The intervention is a 30 minute video of an uninteresting documentary